Global Statistics

According to UN AIDS global statistics, life expectancy of young people living with HIV in the developed countries before treatment with highly active antiretroviral therapy (HAART) was +8 years. Today, the expected impact of HIV treatment on a survival of a young person living with AIDS is +55 years.

As we can see, whereas life expectancy in the high-income developed countries is almost the same as that of a non-infected person, the situation is much more different in the developing world. As a matter of fact, the most alarming data on HIV infections refer to Sub-Saharan Africa, specifically eastern and southern Africa are still the region most affected by the HIV epidemic.

First Health Pharmaceuticals' Cutting-edge Research
Highly Active Antiretroviral Therapy
Traditional Highly Active Antiretroviral Therapy (HAART) treatment is perfectly capable of reducing the viral load in the vascular system to minimal levels. As such, a “pre-cleaning” by HAART, followed by Translation Inhibiting therapy, in combination with a wake-up agent for dormant reservoir cells, could very well prove to be the road to take towards total HIV eradication. The war against HIV will still require joint efforts from many sides. First Health Pharmaceuticals’ novel Translation Inhibitor class of ART compounds offer a true perspective of a better future for millions of HIV/AIDS patients worldwide.

  • Amsterdam meets the 2020 International Goals
    Amsterdam is among the first cities to reach and exceed the UN 90–90–90 targets, which stand for 90% of all people with HIV should have been tested and know that they have HIV; 90% of these people should be receiving treatment; and in 90% of those people on treatment, the virus should be suppressed so that it can no longer be transmitted.

    Although the annual number of HIV diagnoses in the city has declined by nearly half, there is still a significant number of new diagnoses each year among people with advanced infection. Therefore, a major current challenge is to diagnose infections earlier and to link all diagnosed individuals promptly to treatment, according to tha data provided by Stichting HIV Monitoring

  • Sub-Saharan Africa's Severe HIV/AIDS Epidemic
    Sub-Saharan Africa is the world’s most affected region. More than half of people living with HIV globally are home to Eastern and Southern Africa region. Antiretroviral therapy has largely contributed to the rapid decrease in AIDS-related mortality in eastern and southern Africa. In 2016, there were 11.7 million people on antiretroviral therapy (ART) in the region, three times more than the 2010 numbers.

    Nevertheless, AIDS-related illness still remains a leading cause of death in the region. Much more sustained support from international donors in terms of investments and cutting edge scientific research, in addition to further realization of domestic efficiencies, will be needed for ending AIDS in the world’s most affected region.